Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Texas Cancer Center At Medical City
mi
from
Dallas, TX
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Texas Cancer Center At Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Texas Oncology, PA
mi
from
Dallas, TX
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Texas Oncology, PA Bedford
mi
from
Houston, TX
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Texas Oncology, PA Bedford
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Texas Oncology
mi
from
Houston, TX
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Texas Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
North Texas Regional Cancer Center
mi
from
Plano, TX
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
North Texas Regional Cancer Center
mi
from
Plano, TX
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Tyler Cancer Center
mi
from
Tyler, TX
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Northern Utah Associates
mi
from
Ogden, UT
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Northern Utah Associates
mi
from
Ogden, UT
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Virginia Oncology Associates
mi
from
Newport News, VA
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Virginia Oncology Associates
mi
from
Newport News, VA
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Virginia Oncology Associates
mi
from
Norfolk, VA
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Northwest Cancer Specialist - Vancouver
mi
from
Vancouver, WA
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Northwest Cancer Specialist - Vancouver
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  7/22/2014
Northwest Cancer Care Specialists, P.C.
mi
from
Vancouver, WA
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 7/22/2014
Northwest Cancer Care Specialists, P.C.
mi
from
Vancouver, WA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
HOPE Research Institute
mi
from
Phoenix, AZ
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
HOPE Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Arizona Clinical Research Center
mi
from
Tucson, AZ
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Arizona Clinical Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Cancer Care Associates
mi
from
Fresno, CA
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Cancer Care Associates
mi
from
Fresno, CA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
White Memorial Medical Center
mi
from
Los Angeles, CA
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
White Memorial Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Hematology Oncology Associates
mi
from
Oakland, CA
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Hematology Oncology Associates
mi
from
Oakland, CA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Better Health Clinical Research
mi
from
Newnan, GA
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Better Health Clinical Research
mi
from
Newnan, GA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Christie Clinic
mi
from
Champaign, IL
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Christie Clinic
mi
from
Champaign, IL
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Global Scientific Innovations
mi
from
Evansville, IN
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Global Scientific Innovations
mi
from
Evansville, IN
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Montana Cancer Institute Foundation
mi
from
Missoula, MT
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Montana Cancer Institute Foundation
mi
from
Missoula, MT
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
The Center for Clinical Research
mi
from
Winston-Salem, NC
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
The Center for Clinical Research
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Pain Research of Oregon
mi
from
Eugene, OR
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Pain Research of Oregon
mi
from
Eugene, OR
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Hematology Oncology Associatesof Rhode Island
mi
from
Cranston, RI
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Hematology Oncology Associatesof Rhode Island
mi
from
Cranston, RI
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Medical Therapy and Research
mi
from
San Antonio, TX
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Medical Therapy and Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Medical Oncology Associates
mi
from
Spokane, WA
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Medical Oncology Associates
mi
from
Spokane, WA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Compassionate Cancer Care Medical Group INC
mi
from
Corona, CA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
TriWest Research Associates
mi
from
La Mesa, CA
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
TriWest Research Associates
mi
from
La Mesa, CA
Click here to add this to my saved trials
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated:  7/28/2014
Advanced Pharma CR, LLC
mi
from
Miami, FL
NP2 Enkephalin For Treatment of Intractable Cancer Pain
A Phase II, Randomized, Double Blind, Placebo-controlled, Multicenter Study to Investigate the Impact of NP2 in Subjects With Intractable Pain Due to Malignancy
Status: Enrolling
Updated: 7/28/2014
Advanced Pharma CR, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer
A Pilot Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide (99mTc-GP) in Patients With Breast Cancer
Status: Enrolling
Updated:  7/29/2014
Houston Methodist Hospital
mi
from
Houston, TX
The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer
A Pilot Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide (99mTc-GP) in Patients With Breast Cancer
Status: Enrolling
Updated: 7/29/2014
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
New Haven, CT
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Tampa, FL
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Chicago, IL
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Baltimore, MD
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Boston, MA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Chapel Hill, NC
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  7/30/2014
Clinical Research Facility
mi
from
Seattle, WA
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)
A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 7/30/2014
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients
A Pilot Study to Determine the Effectiveness of Bioelectrical Impedance Analysis as a Clinical Assessment Tool of Nutrition Status in Glioblastoma Multiforme Patients (The BEAM Study [BIA Effectiveness as Assessment Tool for Glioblastoma Multiforme (GBM) Patients])
Status: Enrolling
Updated:  7/31/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients
A Pilot Study to Determine the Effectiveness of Bioelectrical Impedance Analysis as a Clinical Assessment Tool of Nutrition Status in Glioblastoma Multiforme Patients (The BEAM Study [BIA Effectiveness as Assessment Tool for Glioblastoma Multiforme (GBM) Patients])
Status: Enrolling
Updated: 7/31/2014
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
University of Southern California
mi
from
Los Angeles, CA
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
NorthShore University HealthSystem
mi
from
Evanston, IL
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
Northwestern Univeristy
mi
from
Evanston, IL
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
Northwestern Univeristy
mi
from
Evanston, IL
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
University of Indiana
mi
from
Indianapolis, IN
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
University of Indiana
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated:  7/31/2014
Boston Med Ctr
mi
from
Boston, MA
Novel Biophotonics Methodology for Colon Cancer Screening
Novel Biophotonics Methodology for Colon Cancer Screening
Status: Enrolling
Updated: 7/31/2014
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults
A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Status: Enrolling
Updated:  8/1/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults
A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Status: Enrolling
Updated: 8/1/2014
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults
A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Status: Enrolling
Updated:  8/1/2014
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults
A Phase II Trial of Peginterferon Alpha-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Status: Enrolling
Updated: 8/1/2014
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
University of Colorado Cancer Center
mi
from
Aurora, CO
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  8/4/2014
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 8/4/2014
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials